Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Virpax Pharmaceuticals ( (VRPX) ) has shared an announcement.
On February 5, 2025, Virpax Pharmaceuticals appointed Charn Deol as an independent director following the resignation of Jaydriane Panis. Mr. Deol, with over 35 years of public company management experience, will also serve as Chair of the Audit Committee and join the Compensation and Nominating and Corporate Governance Committees. His appointment is expected to enhance Virpax’s strategic oversight, leveraging his extensive experience in guiding Canadian companies through public market regulatory processes.
More about Virpax Pharmaceuticals
YTD Price Performance: -21.35%
Average Trading Volume: 3,938,994
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $5.35M
Learn more about VRPX stock on TipRanks’ Stock Analysis page.